Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection

Mark R. Wallace, Ronald B. Moss, H. James Beecham, Christopher J. Grace, Evan M Hersh, Eskild Peterson, Robert Murphy, David H. Shepp, Frederick P. Siegal, John L. Turner, Sharon Safrin, Dennis J. Carlo, Alexandra M. Levine

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In a clinical trial involving asymptomatic, HIV-seropositive subjects treated with either the HIV-1 immunogen (an inactivated, gp120-depleted HIV- 1 virus in incomplete Freund's adjuvant) or an adjuvant control, we examined the relationship between changes in the percentage of CD4 cells over time and early clinical markers of HIV disease progression. Subjects who had an early clinical event were more likely to have a greater decline in the percentage of CD4 cells than those subjects who did not have a clinical event (p = 0.054). The greatest decline in CD4 percentage occurred within 10 weeks prior to a clinical event (mean 11% decrease from baseline). Subjects from the quartile with the greatest decline in CD4 percentage had a fivefold greater risk of having a clinical event than subjects from the quartile with the second largest decline (p = 0.045). These results demonstrate a relationship between changes in the percentage of CD4 cells and early clinical events. Further validation of this association may be useful in clinical monitoring and in evaluating therapies to treat HIV infection.

Original languageEnglish (US)
Pages (from-to)358-362
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume12
Issue number4
StatePublished - 1996

Fingerprint

Virus Diseases
Biomarkers
HIV
HIV-1
HIV Envelope Protein gp120
HIV Infections
Disease Progression
Clinical Trials
Viruses
Therapeutics

Keywords

  • CD4 percent
  • Early HIV clinical events
  • Surrogate markers

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this

Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection. / Wallace, Mark R.; Moss, Ronald B.; Beecham, H. James; Grace, Christopher J.; Hersh, Evan M; Peterson, Eskild; Murphy, Robert; Shepp, David H.; Siegal, Frederick P.; Turner, John L.; Safrin, Sharon; Carlo, Dennis J.; Levine, Alexandra M.

In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 12, No. 4, 1996, p. 358-362.

Research output: Contribution to journalArticle

Wallace, MR, Moss, RB, Beecham, HJ, Grace, CJ, Hersh, EM, Peterson, E, Murphy, R, Shepp, DH, Siegal, FP, Turner, JL, Safrin, S, Carlo, DJ & Levine, AM 1996, 'Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection', Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 12, no. 4, pp. 358-362.
Wallace, Mark R. ; Moss, Ronald B. ; Beecham, H. James ; Grace, Christopher J. ; Hersh, Evan M ; Peterson, Eskild ; Murphy, Robert ; Shepp, David H. ; Siegal, Frederick P. ; Turner, John L. ; Safrin, Sharon ; Carlo, Dennis J. ; Levine, Alexandra M. / Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection. In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1996 ; Vol. 12, No. 4. pp. 358-362.
@article{6a20660716fa48babf4a1ac1b3afecf6,
title = "Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection",
abstract = "In a clinical trial involving asymptomatic, HIV-seropositive subjects treated with either the HIV-1 immunogen (an inactivated, gp120-depleted HIV- 1 virus in incomplete Freund's adjuvant) or an adjuvant control, we examined the relationship between changes in the percentage of CD4 cells over time and early clinical markers of HIV disease progression. Subjects who had an early clinical event were more likely to have a greater decline in the percentage of CD4 cells than those subjects who did not have a clinical event (p = 0.054). The greatest decline in CD4 percentage occurred within 10 weeks prior to a clinical event (mean 11{\%} decrease from baseline). Subjects from the quartile with the greatest decline in CD4 percentage had a fivefold greater risk of having a clinical event than subjects from the quartile with the second largest decline (p = 0.045). These results demonstrate a relationship between changes in the percentage of CD4 cells and early clinical events. Further validation of this association may be useful in clinical monitoring and in evaluating therapies to treat HIV infection.",
keywords = "CD4 percent, Early HIV clinical events, Surrogate markers",
author = "Wallace, {Mark R.} and Moss, {Ronald B.} and Beecham, {H. James} and Grace, {Christopher J.} and Hersh, {Evan M} and Eskild Peterson and Robert Murphy and Shepp, {David H.} and Siegal, {Frederick P.} and Turner, {John L.} and Sharon Safrin and Carlo, {Dennis J.} and Levine, {Alexandra M.}",
year = "1996",
language = "English (US)",
volume = "12",
pages = "358--362",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection

AU - Wallace, Mark R.

AU - Moss, Ronald B.

AU - Beecham, H. James

AU - Grace, Christopher J.

AU - Hersh, Evan M

AU - Peterson, Eskild

AU - Murphy, Robert

AU - Shepp, David H.

AU - Siegal, Frederick P.

AU - Turner, John L.

AU - Safrin, Sharon

AU - Carlo, Dennis J.

AU - Levine, Alexandra M.

PY - 1996

Y1 - 1996

N2 - In a clinical trial involving asymptomatic, HIV-seropositive subjects treated with either the HIV-1 immunogen (an inactivated, gp120-depleted HIV- 1 virus in incomplete Freund's adjuvant) or an adjuvant control, we examined the relationship between changes in the percentage of CD4 cells over time and early clinical markers of HIV disease progression. Subjects who had an early clinical event were more likely to have a greater decline in the percentage of CD4 cells than those subjects who did not have a clinical event (p = 0.054). The greatest decline in CD4 percentage occurred within 10 weeks prior to a clinical event (mean 11% decrease from baseline). Subjects from the quartile with the greatest decline in CD4 percentage had a fivefold greater risk of having a clinical event than subjects from the quartile with the second largest decline (p = 0.045). These results demonstrate a relationship between changes in the percentage of CD4 cells and early clinical events. Further validation of this association may be useful in clinical monitoring and in evaluating therapies to treat HIV infection.

AB - In a clinical trial involving asymptomatic, HIV-seropositive subjects treated with either the HIV-1 immunogen (an inactivated, gp120-depleted HIV- 1 virus in incomplete Freund's adjuvant) or an adjuvant control, we examined the relationship between changes in the percentage of CD4 cells over time and early clinical markers of HIV disease progression. Subjects who had an early clinical event were more likely to have a greater decline in the percentage of CD4 cells than those subjects who did not have a clinical event (p = 0.054). The greatest decline in CD4 percentage occurred within 10 weeks prior to a clinical event (mean 11% decrease from baseline). Subjects from the quartile with the greatest decline in CD4 percentage had a fivefold greater risk of having a clinical event than subjects from the quartile with the second largest decline (p = 0.045). These results demonstrate a relationship between changes in the percentage of CD4 cells and early clinical events. Further validation of this association may be useful in clinical monitoring and in evaluating therapies to treat HIV infection.

KW - CD4 percent

KW - Early HIV clinical events

KW - Surrogate markers

UR - http://www.scopus.com/inward/record.url?scp=9544226548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9544226548&partnerID=8YFLogxK

M3 - Article

C2 - 8673544

AN - SCOPUS:9544226548

VL - 12

SP - 358

EP - 362

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -